Thioredoxin reductase: An emerging pharmacologic target for radiosensitization of cancer

Novel agents are required to increase the radiosensitivity of cancer and improve the outcome of radiotherapy. Thioredoxin (Trx) and thioredoxin reductase (TrxR) reduce the oxidized cysteine thiols in several proteins, which regulate cellular redox, survival, proliferation, DNA synthesis, transcripti...

Descripción completa

Detalles Bibliográficos
Autores principales: Patwardhan, Raghavendra S., Sharma, Deepak, Sandur, Santosh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790659/
https://www.ncbi.nlm.nih.gov/pubmed/35078017
http://dx.doi.org/10.1016/j.tranon.2022.101341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790659/
https://www.ncbi.nlm.nih.gov/pubmed/35078017
http://dx.doi.org/10.1016/j.tranon.2022.101341

Ejemplares similares